(-0.88%) 4 967.23 points
(0.56%) 37 986 points
(-2.05%) 15 282 points
(0.62%) $83.24
(0.17%) $1.760
(0.36%) $2 406.70
(1.29%) $28.75
(-1.17%) $943.30
(-0.14%) $0.938
(-0.28%) $11.01
(0.55%) $0.808
(-0.96%) $93.00
Live Chart Being Loaded With Signals
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products...
Stats | |
---|---|
Today's Volume | 391 000 |
Average Volume | 662 493 |
Market Cap | 678.08M |
EPS | HKD0.0500 ( 2020-09-30 ) |
Last Dividend | HKD0.0798 ( 2023-06-05 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 18.91 |
ATR14 | HKD0.00800 (0.38%) |
FUDANZHANGJIANG Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
FUDANZHANGJIANG Financials
Annual | 2022 |
Revenue: | HKD1.03B |
Gross Profit: | HKD947.10M (91.85 %) |
EPS: | HKD0.130 |
Q3 | 2023 |
Revenue: | HKD185.13M |
Gross Profit: | HKD171.74M (92.77 %) |
EPS: | HKD0.0206 |
Q2 | 2023 |
Revenue: | HKD333.68M |
Gross Profit: | HKD308.17M (92.35 %) |
EPS: | HKD0.0554 |
Q1 | 2023 |
Revenue: | HKD189.15M |
Gross Profit: | HKD171.80M (90.83 %) |
EPS: | HKD0.0100 |
Financial Reports:
No articles found.
FUDANZHANGJIANG Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.0859 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.0798 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0623 | 2015-06-04 |
Last Dividend | HKD0.0798 | 2023-06-05 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 9 | -- |
Total Paid Out | HKD0.566 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.64 | -- |
Div. Sustainability Score | 5.30 | |
Div.Growth Potential Score | 1.701 | |
Div. Directional Score | 3.50 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2342.HK | Ex Dividend Knight | 2023-09-07 | Annually | 0 | 0.00% | |
1314.HK | Ex Dividend Junior | 2023-06-30 | Annually | 0 | 0.00% | |
0375.HK | Ex Dividend Knight | 2023-09-27 | Annually | 0 | 0.00% | |
6127.HK | Ex Dividend Junior | 2023-06-20 | Annually | 0 | 0.00% | |
1876.HK | Ex Dividend Knight | 2023-05-15 | Annually | 0 | 0.00% | |
0900.HK | Ex Dividend Knight | 2023-07-04 | Semi-Annually | 0 | 0.00% | |
0038.HK | Ex Dividend Junior | 2023-06-08 | Sporadic | 0 | 0.00% | |
2778.HK | Ex Dividend Junior | 2023-09-15 | Semi-Annually | 0 | 0.00% | |
1449.HK | Ex Dividend Junior | 2023-05-24 | Insufficient data to determine frequency | 0 | 0.00% | |
0533.HK | Ex Dividend Knight | 2023-09-05 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.187 | 1.500 | 6.26 | 9.40 | [0 - 0.5] |
returnOnAssetsTTM | 0.0649 | 1.200 | 7.84 | 9.41 | [0 - 0.3] |
returnOnEquityTTM | 0.0833 | 1.500 | -0.186 | -0.279 | [0.1 - 1] |
payoutRatioTTM | 0.396 | -1.000 | 6.04 | -6.04 | [0 - 1] |
currentRatioTTM | 3.42 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.32 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.18 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | -286.85 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.0282 | 2.00 | -0.00939 | -0.0188 | [0 - 30] |
freeCashFlowPerShareTTM | -0.103 | 2.00 | -0.0516 | -0.103 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.917 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.174 | 1.000 | 8.52 | 8.52 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.347 | 0.800 | -1.019 | -0.815 | [0.5 - 2] |
Total Score | 5.30 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 10.37 | 1.000 | 9.05 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0833 | 2.50 | -0.119 | -0.279 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.103 | 2.00 | -0.0344 | -0.103 | [0 - 30] |
dividendYielPercentageTTM | 4.17 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.0282 | 2.00 | -0.00939 | -0.0188 | [0 - 30] |
payoutRatioTTM | 0.396 | 1.500 | 6.04 | -6.04 | [0 - 1] |
pegRatioTTM | -0.251 | 1.500 | -5.01 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.0285 | 1.000 | -3.21 | 0 | [0.1 - 0.5] |
Total Score | 1.701 |
FUDANZHANGJIANG
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in pre-clinical studies for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators